1-3 of 3
Fernando Vargas Madueno
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Incidence of Secondary Malignancy after Treatment with Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cell Therapies

Can Jones, Amneh A Fares, Diana Martinez, Jennifer M Logue, Carlos Silva Rondon, Fernando Vargas Madueno, Nina Nguyen, Hugo Francisco Fernandez, Julio C. Chavez, Jose Sandoval-Sus
Journal: Blood
Blood (2024) 144 (Supplement 1): 7241.
https://doi.org/10.1182/blood-2024-206293
Published: 2024
Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 987.
https://doi.org/10.1182/blood-2024-198452
Published: 2024
Journal Articles

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

Stephanie Boisclair, MD, Richie Uba, PharmD, Amanda Brahim, PharmD, Fernando Vargas Madueno, MD, Julio C. Chavez, MD, Jose Sandoval-Sus, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-143226
Published: 2020